Dermata Therapeutics, Inc.
DRMA Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$0.76
KIRA · Stoqly’s AI analyst, in plain words
- Dermata Therapeutics, Inc. lost $7.6M in fiscal 2025.
Market cap
$3.0M
P/E
—
Revenue
—
Net income
−$7.6M
Free cash flow
—
Operating margin
—
Dermata Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$7.6M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Dermata Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- Dermata Therapeutics, Inc.
- CIK
- 0001853816
Dermata Therapeutics, Inc. · DRMA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | −$0.0M | $0.1M | — | — | — |
| Net interest income | −$0.0M | $0.1M | — | — | — |
| Operating margin | 17,230.0% | −15,211.5% | — | — | — |
| Net income | −$7.9M | −$9.6M | −$7.8M | −$12.3M | −$7.6M |
| Net margin | 17,330.0% | −15,111.5% | — | — | — |
| Diluted EPS | — | — | −$39.99 | −$80.32 | −$8.16 |
| Cash | |||||
| Cash from operations | −$5.7M | −$8.8M | −$6.4M | −$11.2M | −$7.8M |
| Share count change | — | — | — | −21.5% | 505.4% |
| Debt and strength | |||||
| Cash and short-term investments | $10.8M | $6.2M | $7.4M | $3.2M | $7.5M |
| Debt incl. finance leases | $0.0M | — | — | — | — |
| Shareholders' equity | $10.1M | $6.0M | $6.4M | $1.6M | $6.2M |
| Current ratio | 7.7x | — | — | — | — |
| Interest coverage | −172.3x | — | — | — | — |
| Returns and quality | |||||
| Return on equity | −228.1% | −119.2% | −126.0% | −310.4% | −194.2% |
| Return on tangible equity | −103.5% | −159.6% | −122.7% | −787.1% | −121.5% |
| Altman Z'' | −1.9 | — | — | — | — |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Dermata Therapeutics, Inc. · DRMA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.76 a share, the company is worth $3.0M.
Source: SEC EDGAR XBRL filings (CIK 0001853816). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.